Price of domestic Pazopanib

Currently, there are domestically produced Pazopanib drugs in China. Common manufacturers include Chia Tai Tianqing, Qilu Pharmaceuticals, etc. The ingredients of the Pazopanib drugs produced are basically the same as those of the original Pazopanib drug. The developed drugs need to be approved by the National Medical Products Administration before they can be put on the market. For specific drug information, patients can consult local hospitals and other places.

The Vascular endothelial growth factor (VEGF) pathway plays an important role in tumor growth and angiogenesis. The U.S. Food and Drug Administration (FDA)approved the VEGF inhibitor pazopanib as a first-line and second-line treatment for advanced renal cell carcinoma and non-adipocyte soft tissue sarcoma (STS), respectively. Pazopanib provides improved quality of life and lower incidence of side effects compared with other VEGF inhibitors. Despite its efficacy in the treatment of renal cell carcinoma, pazopanib is associated with a variety of adverse effects, including gastrointestinal distress, hypothyroidism, bone marrow toxicity, heart failure, myocardial ischemia, and arterial thromboembolic events.

PazopanibThe original drug has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be around 3,000 yuan. The price of pazopanib original drug specifications200mg*30 tablets marketed overseas may be around 1,000 RMB per box (the price may fluctuate due to exchange rates). There are also pazopanib generic drugs produced in other countries. The price of 200mg*30 tablets produced by Bangladesh pharmaceutical factory may be around 500 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.